Chesnara plc (LON:CSN – Get Free Report) insider David Rimmington sold 24,902 shares of Chesnara stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of GBX 252 ($3.17), for a total value of £62,753.04 ($78,825.57).
Chesnara Price Performance
CSN traded down GBX 2.50 ($0.03) on Tuesday, hitting GBX 252 ($3.17). 463,347 shares of the company’s stock traded hands, compared to its average volume of 152,458. The company’s 50 day simple moving average is GBX 260.06 and its 200-day simple moving average is GBX 260.44. The firm has a market cap of £380.14 million, a price-to-earnings ratio of -748.53 and a beta of 0.39. Chesnara plc has a one year low of GBX 242.70 ($3.05) and a one year high of GBX 290 ($3.64). The company has a current ratio of 2.38, a quick ratio of 38.06 and a debt-to-equity ratio of 58.24.
Chesnara Increases Dividend
The company also recently disclosed a dividend, which will be paid on Tuesday, May 28th. Shareholders of record on Thursday, April 11th will be paid a GBX 15.61 ($0.20) dividend. This is an increase from Chesnara’s previous dividend of $8.36. The ex-dividend date is Thursday, April 11th. This represents a yield of 5.96%. Chesnara’s payout ratio is presently -7,058.82%.
About Chesnara
Chesnara plc, together with its subsidiaries, operates in life assurance and pension businesses primarily in the United Kingdom, the Netherlands, and Sweden. It operates through UK, Movestic, Waard Group, and Scildon segments. The company underwrites life risks, such as death, disability, health, and accident; and provides a portfolio of investment contracts for the savings and retirement needs of customers through asset management, as well as general insurance products.
See Also
- Five stocks we like better than Chesnara
- The How and Why of Investing in Biotech Stocks
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What is Put Option Volume?
- Hilton Demonstrates Asset Light is Right for Investors
- When to Sell a Stock for Profit or Loss
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Chesnara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chesnara and related companies with MarketBeat.com's FREE daily email newsletter.